The frequency of atypical Ras pathway mutations in particular was higher than expected overall for class 2 and 3 BRAF-mutant cancers when compared with class 1 cancers (13/709 30.6% vs. 34/112 1.8%, respectively; P < 0.001, Fisher exact test; Table 1). Here, BRAF is linked to cancer.